Research programme: pain therapeutics - Flexion Therapeutics
Alternative Names: FX 007Latest Information Update: 04 Mar 2022
Price :
$50 *
At a glance
- Originator AstraZeneca
- Developer Flexion Therapeutics
- Class Analgesics
- Mechanism of Action TrkA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Musculoskeletal pain; Postoperative pain
Most Recent Events
- 17 Apr 2018 Flexion Therapeutic terminates its licence with AstraZeneca for FX 007 in countries worldwide, effective June 2018
- 05 Mar 2018 Flexion Therapeutics sends notice of licence termination to AstraZeneca for FX 007 in countries worldwide
- 10 Mar 2017 Discontinued - Preclinical for Postoperative pain in USA (Intra-articular)